Effect of Hand Massage on Chronic Kidney Disease Associated Pruritus in Patients Receiving Hemodialysis (MADRID)

Effect of Hand Massage on Chronic Kidney Disease Associated Pruritus in Patients Receiving Hemodialysis: a Mixed Methods Study

Chronic Kidney Disease-Associated Pruritus (CKD-aP) affects about 25% of Swiss hemodialysis patients, most with moderate to severe itching. It negatively impacts sleep, quality of life, and survival. This mixed-methods study will investigate the effect hand massage delivered by nurses on the itch severity, health-related quality of life and sleep compared to usual care in patients on hemodialysis. Fifty-four patients will be randomized to receive either hand massage or verbal attention over three months. Quantitative data (NRS, 5D Itch Scale, KDQOL-SFv1.2) will be collected at baseline, one, and three months. Qualitative interviews with 12 participants who received the hand massage intervention, will explore their experiences. The intervention is safe, non-invasive, and may offer valuable insights into CKD-aP management and pathogenesis.

Study Overview

• Status: Recruiting
• Conditions: Chronic Kidney Disease Associated Pruritus
• Intervention / Treatment: Other: Hand-massage

Detailed Description

Chronic Kidney Disease Associated Pruritus (CKD-aP) represents a distressing skin itch symptom that affects 20-42% of adults on dialysis. We recently conducted the first CKD-aP prevalence study in Switzerland. Results showed that 25% of individuals on hemodialysis experience CKD-aP with 80% suffering from moderate to severe itching. CKD-aP is associated with sleep disturbances, compromised quality of life, social isolation and increased risk of hospitalization and death. CKD-aP may be related to increased uremic toxins, endogenous opioid or immune system dysregulation, peripheral neuropathy with abnormal cutaneous innervation and nerve conduction. In this context, the effect of non-pharmacological management approaches like hand massage on nerve conduction, autonomic stress responses and skin inflammation deserve more attention. Few studies have evaluated the effect of short-term massage (3-4 weeks) on CKD-aP and showed improvement on outcomes evaluated 48 hours after the intervention. The study will be offered to all eligible CKD-aP patients; however, a balanced sex distribution is unlikely due to the male predominance in this population.

This study does not present any risks related to physical or psychological harm to participants. Participants will benefit from a promising non-invasive complementary therapy. Additionally, this study may contribute to a better understanding of the CKD-aP pathogenesis.

The primary objective of this study is to determine whether hand-massage by nurses has an effect on itch severity, Health Related Quality of Life (HRQoL) and sleep in hemodialysis patients with CKD-aP, at one and three months, as compared to usual care, and to explore the lived experience of patients receiving the hand-massage intervention.

A sequential multicenter Explanatory Mixed Methods design will be used. A randomized controlled trial design with two study arms will be conducted first (phase 1), followed by descriptive qualitative research (phase 2).

Phase 1: A total sample size of 54 participants (intervention group n=27; control group n= 27) will be recruted for the RCT. Phase 2: 12 participants from the intervention group who completed the intervention will be recruited to participate in the individual semi-structured interviews.

Participants randomized to the intervention group (n=27) will receive hand-massage that consists of 10 min hand-massage, three times/week for the first month, then once/week for the two consecutive months.

Participants assigned to the control group will receive uninterrupted attention from the nurse via a conversation without use of physical touch for 10 min, three times /week for the first month, then once/month for the two consecutive months.

Questionnaires will be administered by the research assistant who will be blinded to group allocations. Data will be collected at baseline, at one month and at three months, for all outcomes.

Phase 2: Participants from the intervention group who completed the hand-massage intervention will be recruited by the project manager or the research assistant to participate in individual semi-structured interviews.The interviews will be recorded, transcribed and coded using MaxQDA software, enabling a thematic content analysis.

Statistical analyses will be performed in Stata v16 on an intention-to-treat basis. Descriptive statistics will summarize baseline characteristics; between-group differences will be tested with t-tests Repeated measures ANOVA with one between-groups factor (group assignment) and one within-groups factor (time) will be carried out to assess changes in continuous outcome within-subjects across observations. Sex and gender will be recorded and reported in line with HRA/swiss-ethics guidance; subgroup analyses will be explored where numbers allow, acknowledging that balanced sex distribution is unlikely given the epidemiology of the dialysis population.

• Study Type: Interventional
• Enrollment (Estimated): 54
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nancy Helou, PhD; Phone Number: 0787833827; Email: nancy.helou@hesav.ch
• Study Contact Backup: Name: Michael Cordey, MS; Email: michael.cordey@hesav.ch

Study Locations

• Switzerland
  • Geneva, Switzerland, 1205
    • Not yet recruiting
    • HUG
    • Contact: Emma Ollier
    • Contact: Email: emma.ollier@hug.ch
  • Canton of Vaud
    • Lausanne, Canton of Vaud, Switzerland, 1011
      • Recruiting
      • CHUV
      • Contact: Jerome Pays
      • Contact: Email: Jerome.Pays@chuv.ch
    • Vevey, Canton of Vaud, Switzerland, 1800
      • Recruiting
      • Dialyse Riviera
      • Contact: Michael Esteves
      • Contact: Email: michael.esteves@dialyse-riviera.ch
    • Yverdon-les-Bains, Canton of Vaud, Switzerland, 1400
      • Recruiting
      • Etablissements hospitaliers du Nord Vaudois - Hôoital d'Yverdon-les-Bains eHnv
      • Contact: Pauline Van Der Weid, BSN; Phone Number: +41244245225; Email: pauline.vanderweid@ehnv.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults ≥18 years
• on hemodialysis ≥ three months
• able to communicate in French
• diagnosed with CKD-aP based on VAS
• signed informed consent

Exclusion Criteria:

• Participants with cognitive impairment -
• participants who have been prescribed CKD-aP medications after enrollment in study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Hand-massage; Participants randomized to the intervention group (n=27) will receive hand-massage that consists of 10 min hand-massage, two times/week for the first month, then once/week for the two consecutive months, at any time during the hemodialysis session.	Other: Hand-massage; Hand-massage involves engagement with the patient using an enveloping contact on the whole hand and the forearm by means of rhythmic and circular movements, followed by an application of a hand cream or essential oil to the patient's forearm, wrist, palm and back of hand, and fingers using the same movements. The massage applies moderate pressure to the forearm, light gestures on the wrist and the back of the hand, and moderate pressure on the palm and fingers. It ends with a gradual slowing of the manipulations
No Intervention: Control; Participants assigned to the control group (n=27) will receive uninterrupted attention from the nurse via a conversation without use of physical touch for 10 min, two times /week for the first month, then once/month for the two consecutive months, at any time during the hemodialysis session

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Itch severity and itch related quality of life	5D itch scale consists of 5-domains (Disability, Distribution, Duration, Degree, and Direction), 5 point-Likert scale designed to measure itch severity and itch-related QoL with an overall score range from 5 to 25. Lower scores indicate less itch severity and a better QoL.	at baseline, 1 month, 3 months
Health related quality of life (HRQoL)	The Kidney Disease Quality of Life Short Form (KDQOL-SF)™v1.2 questionnaire, a SF-36 derived short-form will be used to measure HRQoL. It is a self-administered 12-question survey assessing eight domains of physical (limitations in physical activities because of health problems, in social activities because of physical or emotional problems, in usual role activities because of physical health problems, bodily pain), and mental health (psychological distress and well-being, limitations in usual role activities because of emotional problems, vitality, and general health perceptions. Scores range between 0-100 and higher scores indicate better HRQoL.	at baseline, 1 month, 3 months
Sleep quality	Sleep quality will be assessed using the Kidney Disease Quality of Life Short form (KDQOL-SF)™v1.2 Sleep Subscale, composed of four items evaluating sleep quality, difficulty falling asleep, waking up during the night, and feeling rested upon waking. Scores for each item are transformed to a 0-100 scale, with higher scores indicating better sleep quality.	at baseline, 1 month, 3 months
Itch severity	The NRS will also be used to measure CKD-aP severity. It includes two questions. The first refers to the average itch intensity during the last 24h and the second refers to the WI-NRS and addresses the worst itch intensity experienced during the last 24h. VAS score ranges from 0 (not itchy) to 10 (extremely itchy); severity can be classified into five categories: 1) 0 =no itch, 2) 0.1-2.9 points =mild itch, 3) 3.0-6.9 points =moderate itch, 4) 7.0-8.9 points =severe itch, and 5) 9.0-10.0 points =very severe itch	at baseline, 1 month, 3 months

Collaborators and Investigators

• Sponsor: University of Applied Sciences of Western Switzerland
• Collaborators: Swiss National Science Foundation

Study record dates

Study Major Dates

• Study Start (Actual): December 17, 2025
• Primary Completion (Estimated): November 30, 2026
• Study Completion (Estimated): June 30, 2027

Study Registration Dates

• First Submitted: December 17, 2025
• First Submitted That Met QC Criteria: December 17, 2025
• First Posted (Actual): December 31, 2025

Study Record Updates

• Last Update Posted (Actual): March 16, 2026
• Last Update Submitted That Met QC Criteria: March 12, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 131465

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No